Conference preview: 12th Pharma & Biotech Patent Litigation

The event comes at a significant time for European IP, with political uncertainty and the current state of IP proving a series of challenges for pharmaceutical and biotech companies conducting business in Europe.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

UKIPO extends funding for specialist IP crime unit as counterfeit risks grow

10 March 2026 UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.

Big Pharma

The curtain closes on three major drug disputes

11 February 2026 Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.

Big Pharma

The clinical trial dilemma: Navigating European practice

27 November 2025 Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.

More features

Novo ends Hims & Hers dispute with deal for blockbuster weight-loss drugs

UKIPO extends funding for specialist IP crime unit as counterfeit risks grow

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

Abbott IP chief: ‘Firms without AI policies scare me’

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

Emotional Perception: What next for patent holders?

LSPN Awards 2026 finalists revealed

Natera and a rival draw the line under five-year fight

Conference preview: 12th Pharma & Biotech Patent Litigation

More on this story

Editor's picks

Editor's picks

More features